We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+12.05%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.07B
AUM Growth
-$249M
Cap. Flow
-$414M
Cap. Flow %
-13.47%
Top 10 Hldgs %
34.44%
Holding
117
New
6
Increased
34
Reduced
30
Closed
8

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$18.4M
2
ZBIO
Zenas BioPharma
ZBIO
+$15.8M
3
SMMT icon
Summit Therapeutics
SMMT
+$14.5M
4
NUVL
Nuvalent
NUVL
+$14.4M
5
CYTK icon
Cytokinetics
CYTK
+$11.5M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$168M
2
IDXX icon
Idexx Laboratories
IDXX
+$58.2M
3
EVH icon
Evolent Health
EVH
+$51.7M
4
BSX icon
Boston Scientific
BSX
+$28.2M
5
ACHC icon
Acadia Healthcare
ACHC
+$26.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.71%
2 Consumer Staples 1.99%
3 Financials 0.11%
4 Industrials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INZY
51
DELISTED
Inozyme Pharma
INZY
$19.9M 0.65%
3,802,883
+104,509
+3% +$542K
VERA icon
52
Vera Therapeutics
VERA
$2.27B
$17M 0.55%
383,492
+2,300
+0.6% +$87.3K
DYN icon
53
Dyne Therapeutics
DYN
$4.95B
$16.6M 0.54%
461,028
– –
NVO
54
Novo Nordisk
NVO
$211B
$15.7M 0.51%
132,000
-15,500
-11% -$2.07M
ZBIO
55
Zenas BioPharma
ZBIO
$2.02B
$14.9M 0.48%
+878,667
New +$15.8M
APLT
56
DELISTED
Applied Therapeutics
APLT
$14.8M 0.48%
1,746,449
+191,445
+12% +$1.13M
CRNX icon
57
Crinetics Pharmaceuticals
CRNX
$8.93B
$14.8M 0.48%
289,400
– –
PHVS icon
58
Pharvaris
PHVS
$2.43B
$14M 0.46%
756,931
– –
FOLD
59
DELISTED
Amicus Therapeutics
FOLD
$13.4M 0.43%
1,250,280
+31,700
+3% +$345K
JNJ icon
60
Johnson & Johnson
JNJ
$631B
$13M 0.42%
80,000
-90,000
-53% -$14.3M
CGEM icon
61
Cullinan Oncology
CGEM
$1.18B
$12.3M 0.4%
736,914
+78,576
+12% +$1.39M
BCAX
62
Bicara Therapeutics
BCAX
$1.82B
$11.4M 0.37%
+445,975
New +$11.4M
ELVN icon
63
Enliven Therapeutics
ELVN
$4.35B
$10.9M 0.36%
428,571
– –
NMRA icon
64
Neumora Therapeutics
NMRA
$300M
$10.9M 0.36%
828,101
+68,094
+9% +$794K
CYTK icon
65
Cytokinetics
CYTK
$10.5B
$10.9M 0.35%
+206,108
New +$11.5M
BMRN icon
66
BioMarin Pharmaceuticals
BMRN
$13.3B
$10.6M 0.35%
151,000
– –
PRTA icon
67
Prothena Corp
PRTA
$468M
$10.5M 0.34%
625,048
– –
CMPX icon
68
Compass Therapeutics
CMPX
$400M
$10.4M 0.34%
5,629,239
+115,451
+2% +$144K
KRYS icon
69
Krystal Biotech
KRYS
$9.81B
$10.2M 0.33%
55,861
-49,708
-47% -$9.58M
AUPH icon
70
Aurinia Pharmaceuticals
AUPH
$2.06B
$8.65M 0.28%
1,179,740
– –
JSPR icon
71
Jasper Therapeutics
JSPR
$26.6M
$8.64M 0.28%
459,088
+54,753
+14% +$1.09M
NVAX icon
72
Novavax
NVAX
$1.3B
$8.21M 0.27%
650,000
-25,000
-4% -$323K
XNCR icon
73
Xencor
XNCR
$1.6B
$8.06M 0.26%
+401,013
New +$7.53M
NVRO
74
DELISTED
NEVRO CORP.
NVRO
$7.72M 0.25%
1,381,500
– –
DVAX
75
DELISTED
Dynavax Technologies
DVAX
$6.74M 0.22%
605,013
-687,624
-53% -$7.58M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Rock Springs Capital Management held 117 positions worth $3.07B, down 7.5% from $3.32B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management withdrew a net $414M in Q3 2024, closing 8 positions and reducing 30 holdings. Its most notable exit was Idexx Laboratories, an estimated $58.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Rock Springs Capital Management opened a new position in Zenas BioPharma worth $14.9M.

  • Rock Springs Capital Management's largest Q3 2024 buy was Zenas BioPharma: 878,667 shares worth $14.9M.
  • Rock Springs Capital Management added most to Eli Lilly in Q3 2024, an estimated $18.4M increase.
  • Rock Springs Capital Management's biggest Q3 2024 reduction was Blueprint Medicines, cutting an estimated $168M.
  • Rock Springs Capital Management fully exited Idexx Laboratories in Q3 2024, selling an estimated $58.2M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $3.07B portfolio in Q3 2024.
  • Rock Springs Capital Management opened 6 new positions and closed 8 in Q3 2024.
  • Rock Springs Capital Management's portfolio value fell 7.5% quarter-over-quarter to $3.07B.

Based on Rock Springs Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.